JT
GLUE icon

Jupiter Topco’s Monte Rosa Therapeutics GLUE Stock Holding History

Jupiter Topco’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26M Buy
+1,072,494
New +$20.3M 0.01% 587

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Jupiter Topco's GLUE Position: Q2 2026 in Review

Jupiter Topco opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 1,072,494 shares worth $26M. The stake represents 0.01% of the portfolio and ranks #587 among its holdings.

175 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Jupiter Topco held 1,072,494 shares of Monte Rosa Therapeutics worth $26M as of Q2 2026.
  • Monte Rosa Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Monte Rosa Therapeutics made up 0.01% of Jupiter Topco's portfolio in Q2 2026, its #587 holding.
  • 175 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.